Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of Ramucirumab Biosimilar vs Cyramza in Healthy Male Volunteers
NCT05800418Phase 1Completed
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Nov 2019
- Primary completion
- Feb 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ramucirumab in gastric cancer (GC), non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) (2 arms), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoint: Area Under the Serum Concentration-Time Curve From Time Zero to Time t at 1680 hours. Started Nov 2019; status: completed.
02
Drugs
ramucirumab
03
Conditions
gastric cancer (GC)non-small cell lung cancer (NSCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05800418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05800418.